New Set Of MDMA Analogs To Hit The Clinic: These Are The Latest Positive Findings
New Set Of MDMA Analogs To Hit The Clinic: These Are The Latest Positive Findings
Psychedelics biotech Mydecine Innovations Group (OTC:MYCOF) is advancing the development of its novel compounds family of next-gen MDMA analogs.
迷幻生物技術Mydecine創新集團(場外交易代碼：MYCOF)正在推進其新型化合物家族的開發新一代MDMA類似物。
So far, Mydecine's compounds show promising pharmacokinetics (PK) and pharmacodynamics (PD) in preclinical models.
到目前為止，Mydecine的化合物在臨床前模型中顯示出良好的藥代動力學(PK)和藥效學(PD)。
The new data on the MYCO-006 family shows "considerably" shorter half-life (a projected estimated 1 to 2 hours) and accelerated onset (four-fold is projected) while retaining MDMA's desirable features toward potentially treating PTSD, anxiety, depression, addiction and chronic pain.
最新數據顯示MYCO-006系列展示會“相當”短的半衰期(預計1至2小時)和加速發作(預計將有四個方面)，同時保留MDMA的可取功能，以潛在地治療創傷後應激障礙、焦慮、抑鬱、成癮和慢性疼痛。
This combination will "significantly improve" the compounds' potential use in already-existing medical and clinical settings versus new, specialized facilities. Clinicians can use the drugs to improve treatment efficacy while eliminating the need for further post-session patient monitoring. This is expected to reduce costs in terms of physician hours, the company said.
這種結合將“顯著提高”化合物在現有醫療和臨床環境中的潛在用途，而不是新的專門設施。臨床醫生可以使用這些藥物來提高治療效果，同時消除對會後患者進一步監測的需要。該公司表示，這預計將降低醫生工作時間的成本。
As such, Mydecine has filed several patent claims for these drug candidates covering composition of matter and granting a 20-years use exclusivity.
因此，Mydecine已經為這些候選藥物申請了幾項專利，涉及物質的組成，並授予20年的使用排他性。
CEO Joshua Bartch stated the company is confident MAPS will receive FDA clearance for MDMA this year, following the compound's demonstrated much higher efficacy rates than existing treatments for PTSD and other indications.
首席執行官約書亞·巴奇該公司表示，該公司有信心MAPS今年將獲得FDA對MDMA的批准，此前該化合物對創傷後應激障礙和其他適應症的有效率遠遠高於現有的治療方法。
Bartch says "Gen-1" MDMA therapy might come with "serious flaws" such as not being able to offer the medicine in the current medical infrastructure — something that would provide access to "a substantially larger proportion of the suffering population" as well as "significantly increase the volume of treatments."
巴奇稱“第一代”MDMA療法可能會伴隨著“嚴重缺陷”，比如無法在目前的醫療基礎設施中提供這種藥物--這將為“更大比例的受苦人群”提供服務，並“顯著增加治療數量”。
ICYMI, exclusive coverage from the Benzinga Psychedelics Capital Conference 2023:
ICYMI，來自本辛加迷幻資本會議2023年的獨家報道：
-
Johns Hopkins Professor: Psychedelic Medicine Could Get Messy, Calls For 'Right, Smart, Non-Restrictive, Yet Preventive' Regulations
-
Investing In The Unique Growth Market Of Psychedelics
-
MDMA Therapy Experts Debate Upcoming Approval, Psychedelic Market Opps
-
Ketamine Therapy Leaders Share Bold Vision For Future Of Psychedelics
-
In Reinventing Mental Health & Next-Gen Psychedelics, 'Access And Clinical Data Are Key'
-
Fireside With Enveric Biosciences's Dr. Tucker, Unlocking Psychedelic Healing Benefits
-
Making The World A Better Place, How Psychedelics Are Helping
-
約翰霍普金斯大學教授：迷幻藥可能會變得雜亂無章，呼籲制定“正確、聰明、非限制性但又具有預防性”的法規
-
投資迷幻藥獨特的成長型市場
-
MDMA治療專家辯論即將獲得的批准，迷幻藥市場行情
-
氯胺酮治療領導者分享迷幻藥未來的大膽願景
-
在重塑心理健康和下一代迷幻藥中，獲取和臨床數據是關鍵
-
與Enveric Biosciences的Dr.Tucker合作，解鎖迷幻治療的好處
-
讓世界變得更美好，迷幻藥是如何幫助你的
Photo: Benzinga edit with photo by Blue Planet Studio and ANDREI ASKIRKA on Shutterstock.
照片：Benzinga編輯與Blue Planet Studio和Andrei ASKIRKA在Shutterstock上的照片。